Extended rituximab therapy in Waldenström's macroglobulinemia.

@article{Treon2005ExtendedRT,
  title={Extended rituximab therapy in Waldenstr{\"o}m's macroglobulinemia.},
  author={Steven P Treon and Christos Emmanouilides and Eva K Kimby and Abigail S Kelliher and Frederic Preffer and Andrew Branagan and Kenneth C. Anderson and Stanley R. Frankel},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2005},
  volume={16 1},
  pages={132-8}
}
BACKGROUND Waldenström's macroglobulinemia (WM) is a CD20 expressing B-cell malignancy represented by the pathological diagnosis of IgM secreting lymphoplasmacytic lymphoma. Major response rates of 30% have been reported in most studies with standard dose rituximab, i.e. 4 weekly infusions at 375 mg/m(2)/week. METHODS In an effort to increase rituximab activity in WM, an extended dose schedule employing two sets of four (375 mg/m(2)/week) infusions at weeks 1-4 and 12-16 was evaluated… CONTINUE READING
63 Citations
26 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 63 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 26 references

CD20 directed serotherapy induces responses and facilitates hematological recovery in patients with Waldenstrom’s macroglobulinemia

  • SP Treon, DB Agus, B Link
  • J Immunother
  • 2001
Highly Influential
3 Excerpts

Rituximab for Waldenstrom’s macroglobulinemia (E3A98): An ECOG phase II pilot study for untreated or previously treated patients

  • MA Gertz, M Rue, E Blood
  • 148a (Abstr)
  • 2003

Similar Papers

Loading similar papers…